Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Operating Leases (2020 - 2023)

Insight Molecular Diagnostics (IMDX) has disclosed Operating Leases for 4 consecutive years, with $2.1 million as the latest value for Q4 2023.

  • Quarterly Operating Leases fell 22.98% to $2.1 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2023, down 22.98% year-over-year, with the annual reading at $2.1 million for FY2023, 22.98% down from the prior year.
  • Operating Leases hit $2.1 million in Q4 2023 for Insight Molecular Diagnostics, down from $2.6 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $4.3 million in Q4 2020 to a low of $2.1 million in Q4 2023.
  • Historically, Operating Leases has averaged $3.3 million across 4 years, with a median of $3.3 million in 2022.
  • Biggest five-year swings in Operating Leases: dropped 13.83% in 2022 and later fell 23.33% in 2023.
  • Year by year, Operating Leases stood at $4.3 million in 2020, then fell by 17.79% to $3.5 million in 2021, then decreased by 23.02% to $2.7 million in 2022, then dropped by 22.98% to $2.1 million in 2023.
  • Business Quant data shows Operating Leases for IMDX at $2.1 million in Q4 2023, $2.6 million in Q1 2023, and $2.7 million in Q4 2022.